Nanjing Novlead Biotechnology Co., Ltd.

南京诺令生物科技股份有限公司

Develops and commercializes inhaled nitric oxide (iNO) therapy devices for cardiopulmonary indications in China, with core product iNOwill approved by NMPA in 2022 and CE-certified in 2025, serving ICU and critical care for severe cardiopulmonary disease.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Leased property
• Owned property & construction permits
• Social insurance & housing fund
• Other employment
• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Distribution model
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Non-IFRS measures and adjustments
• Related-party transactions and balances
• Chapter 18A biotech